JP2019537603A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537603A5
JP2019537603A5 JP2019523847A JP2019523847A JP2019537603A5 JP 2019537603 A5 JP2019537603 A5 JP 2019537603A5 JP 2019523847 A JP2019523847 A JP 2019523847A JP 2019523847 A JP2019523847 A JP 2019523847A JP 2019537603 A5 JP2019537603 A5 JP 2019537603A5
Authority
JP
Japan
Prior art keywords
tetrahydro
pyrazole
naphthylidine
ethyl
carboxyamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523847A
Other languages
English (en)
Japanese (ja)
Other versions
JP7128811B2 (ja
JP2019537603A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/060390 external-priority patent/WO2018089358A1/en
Publication of JP2019537603A publication Critical patent/JP2019537603A/ja
Publication of JP2019537603A5 publication Critical patent/JP2019537603A5/ja
Application granted granted Critical
Publication of JP7128811B2 publication Critical patent/JP7128811B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523847A 2016-11-08 2017-11-07 アルファvインテグリン阻害剤としてのアゾールアミドおよびアミン Active JP7128811B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662418838P 2016-11-08 2016-11-08
US62/418,838 2016-11-08
PCT/US2017/060390 WO2018089358A1 (en) 2016-11-08 2017-11-07 Azole amides and amines as alpha v integrin inhibitors

Publications (3)

Publication Number Publication Date
JP2019537603A JP2019537603A (ja) 2019-12-26
JP2019537603A5 true JP2019537603A5 (enExample) 2020-12-03
JP7128811B2 JP7128811B2 (ja) 2022-08-31

Family

ID=60409437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523847A Active JP7128811B2 (ja) 2016-11-08 2017-11-07 アルファvインテグリン阻害剤としてのアゾールアミドおよびアミン

Country Status (14)

Country Link
US (1) US10851098B2 (enExample)
EP (1) EP3538527B1 (enExample)
JP (1) JP7128811B2 (enExample)
KR (1) KR102510858B1 (enExample)
CN (1) CN110167933B (enExample)
AU (1) AU2017359028A1 (enExample)
BR (1) BR112019009245A2 (enExample)
CA (1) CA3042684A1 (enExample)
EA (1) EA201991121A1 (enExample)
ES (1) ES2898835T3 (enExample)
IL (1) IL266465A (enExample)
MA (1) MA46746A (enExample)
MX (1) MX2019005234A (enExample)
WO (1) WO2018089358A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10604520B2 (en) 2016-09-07 2020-03-31 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
KR20190100232A (ko) 2016-12-29 2019-08-28 세인트 루이스 유니버시티 인테그린 길항제
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
IL316954A (en) 2017-02-28 2025-01-01 Morphic Therapeutic Inc (Alpha-V)(beta-6)integrin inhibitors
UY38353A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibición de integrina alfavbeta6
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
UY38352A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
HUE070112T2 (hu) 2018-10-30 2025-05-28 Gilead Sciences Inc 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4β7インテグリンの阻害のための化合物
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ, インコーポレイテッド α4β7インテグリンの阻害のための化合物
GB202010626D0 (en) * 2020-07-10 2020-08-26 Univ Nottingham Compound
US20240174603A1 (en) * 2021-02-08 2024-05-30 Rappta Therapeutics Oy Modulators of protein phosphatase 2a (pp2a) and methods using same
WO2022192545A1 (en) * 2021-03-10 2022-09-15 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
AU1523199A (en) * 1997-11-26 1999-06-15 Du Pont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as alphavbeta3 antagonists
EP1047425A4 (en) 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
AU748621B2 (en) 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
DZ3263A1 (fr) * 1999-06-02 2000-12-07 Merck & Co Inc Antagonistes du recepteur de l'alpha v integrine
US7119098B2 (en) 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
CA2436130A1 (en) 2001-01-29 2002-08-08 Ortho-Mcneil Pharmaceutical, Inc. Substituted indoles and their use as integrin antagonists
JP4554364B2 (ja) 2002-08-16 2010-09-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インテグリンと選択的に結合するピペリジニル化合物
RU2388472C2 (ru) 2003-10-01 2010-05-10 Мерк Патент Гмбх Антагонисты альфаvбета3 и альфаvбета6 интегринов в качестве антифибротических агентов
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
US20080045521A1 (en) 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
ITFI20100019A1 (it) * 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
CN104640850A (zh) 2012-10-26 2015-05-20 霍夫曼-拉罗奇有限公司 3,4-二取代的1h-吡唑和4,5-二取代的噻唑的syk抑制剂
ES2651162T3 (es) * 2013-02-07 2018-01-24 Scifluor Life Sciences, Inc Antagonistas fluorados de integrina
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
CA2981371A1 (en) * 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
WO2018089353A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as alpha v integrin inhibitors

Similar Documents

Publication Publication Date Title
JP2019537603A5 (enExample)
RU2436780C2 (ru) Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы
RU2439068C2 (ru) Модуляторы mglur5
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
JP2010505832A5 (enExample)
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
RU2011105151A (ru) Азольные соединения
JP2019537594A5 (enExample)
JP2017522374A5 (enExample)
JP2016504378A5 (enExample)
JP2007519754A5 (enExample)
RU2012125372A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
JP2018509418A5 (enExample)
JP2003528070A5 (enExample)
JP2006500348A5 (enExample)
RU2481330C2 (ru) Азотсодержащее ароматическое гетероциклическое соединение
JP2019518036A5 (enExample)
JP2012519179A5 (enExample)
RU2009117705A (ru) Производные 2-аминокарбонилпиридина
JP2008535871A5 (enExample)
RU2007141892A (ru) 5-метил-1-(замещенный фенил)-2-(1н)-пиридон для производства медикаментов для лечения фиброза в органах и тканях
RU2008141509A (ru) Mglur5 модуляторы 1
JP2018515555A5 (enExample)
JP2006514942A5 (enExample)
JP2007530690A5 (enExample)